HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elizabeth Arden

This article was originally published in The Rose Sheet

Executive Summary

Offering of nearly 2.6 mil. shares of common stock at $19.50 per share is complete, firm announces June 15. Unilever NV affiliates sold approximately 2.3 mil shares, and Arden sold 231,793 shares pursuant to an over-allotment option granted by the firm and exercised by the underwriter on June 10 (1"The Rose Sheet" June 14, 2004, In Brief). Shares sold comprise the remainder of common stock underlying firm's outstanding Series D Convertible Preferred stock. Since no shares of the Series D Convertible Preferred stock remain outstanding, Arden will not have to pay the 5% dividend on the outstanding liquidation and expects to incur a non-cash charge for the five-month period ending June 30 of approximately $19.2 mil. Charge will be the last associated with Series D Preferred Stock, company says...

Offering of nearly 2.6 mil. shares of common stock at $19.50 per share is complete, firm announces June 15. Unilever NV affiliates sold approximately 2.3 mil shares, and Arden sold 231,793 shares pursuant to an over-allotment option granted by the firm and exercised by the underwriter on June 10 (1 'The Rose Sheet' June 14, 2004, In Brief). Shares sold comprise the remainder of common stock underlying firm's outstanding Series D Convertible Preferred stock. Since no shares of the Series D Convertible Preferred stock remain outstanding, Arden will not have to pay the 5% dividend on the outstanding liquidation and expects to incur a non-cash charge for the five-month period ending June 30 of approximately $19.2 mil. Charge will be the last associated with Series D Preferred Stock, company says....

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel